These neoantigens may represent diagnostic biomarkers [144], and several lines of evidence indicate that HLA uLigands may also serve as promising immunotherapy targets [6,17], similar to classical neoantigens, as recently described for the KRAS G12D mutation in pancreatic cancer [141]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.